Researchers at the University of California, School of Medicine found a new combination that effectively treats hepatitis C (HCV) patients co-infected with human immunodeficiency virus type 1 (HIV).
Although some previous studies have suggested an increased risk of bladder cancer with use of the diabetes drug pioglitazone, analyses that included nearly 200,000 patients found no statistically significant increased risk, however a small increased risk could not be excluded, according to a study in the July 21 issue of JAMA.
Researchers have found an association between treatment with the antibiotic dicloxacillin and a decrease in international normalized ratio (INR; a measure of blood coagulation) levels among patients taking the vitamin K antagonists warfarin or phenprocoumon, according to a study in the July 21 issue of JAMA.
Nearly a third of breast cancer survivors in Appalachia are not taking the critical, potentially life-saving follow-up treatment – despite having insurance that would pay for it, a troubling new study has found.
In recent years, immunotherapy has emerged as a promising treatment for certain cancers. Now this strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable. The results appeared in a study published online today in Nature Medicine.
A new drug acts as a roadblock for malaria, curing mice of established infection, according to researchers. Treatment was not associated with obvious side effects, suggesting that the drug may also be safe and effective in humans.
A team of researchers, including neuroscientists from Washington University School of Medicine in St. Louis, has developed a wireless device the width of a human hair that can be implanted in the brain and activated by remote control to deliver drugs to brain cells. The technology, demonstrated for the first time in mice, one day may be used to treat pain, depression, epilepsy and other neurological disorders in people by targeting therapies to specific brain circuits.
Researchers at UT Southwestern Medical Center and in Australia have shown that a drug currently in testing shows potential to cure malaria in a single dose and offers promise as a preventive treatment as well.
...as a cost effective prevention of more serious cardiovascular-related health issues
New research reports that diabetes drug metformin can treat portal hypertension--high blood pressure in the liver resulting from cirrhosis. This study adds to the growing body of evidence showing that use of metformin goes beyond treating type 2 diabetes.
Benzodiazepine drugs are widely used in patients with posttraumatic stress disorder (PTSD), but available evidence suggests that they are not effective—and may even be harmful, concludes a systematic review and meta-analysis in the July Journal of Psychiatric Practice. The journal is published by Wolters Kluwer.
A new study has identified promising compounds that could successfully treat depression in less than 24 hours while minimizing side effects. The compounds could offer significant advantages over current antidepressant medications.
Research with human tissue and cells suggests that genetic variations, in addition to failure to comply with treatment regimens, may account for some failures of an anti-HIV drug to treat and prevent HIV infection.
Other topics include the importance of nursing in medicine, more efficient drug development, studying the arts improves medical care, and more...
Other topics include autism research, biofuel sources, nutrition supplements, and more...
A new study led by University of Kentucky researchers suggests a new approach to develop highly-potent drugs which could overcome current shortcomings of low drug efficacy and multi-drug resistance in the treatment of cancer as well as viral and bacterial infections.
Many people believe that phase I trials with healthy volunteers are very risky and because they pose risks with no benefits, unethical. But how risky are such trials? Less than 1% of 11,000 healthy volunteers who participated in 394 phase I trials for new drugs experienced serious complications, according to a new meta-analysis of participants in non-cancer, phase I medication trials. In addition, none of the volunteers died or suffered persistent disabilities linked to the experimental drugs.
Tests have shown that a new cancer drug, FY26, is 49 times more potent than the clinically used treatment Cisplatin.
Researchers at the University of Adelaide have discovered a new method for culturing stem cells which sees the highly therapeutic cells grow faster and stronger.
A review article published on the journal Oncotarget focusing on RB role in apoptosis provides a comprehensive overview on the role of RB proteins in the coordinated control of cell decisions.
The "placebo effect" is often described as events that occur when patients show improvement from treatments that contain no active ingredients. A "Perspectives" article in the July 2 issue of The New England Journal of Medicine proposes that placebo effects be more broadly defined to reflect their role as a valuable component of medical care.
Researchers from the Icahn School of Medicine at Mount Sinai have discovered that histones are steadily replaced in brain cells throughout life
Long-term use of naproxen (ALEVE), a type of nonsteroidal anti-inflammatory drug (NSAID), is often prescribed for chronic pain conditions such as osteoarthritis. However, because of NSAID-related gastrointestinal problems including stomach and intestinal inflammation and ulcers, many are unable to tolerate ongoing use. A new study, published in the American Journal of Physiology–Gastrointestinal and Liver Physiology, finds that a naproxen-derivative may provide both symptom relief and gastrointestinal protection. The research is highlighted as one of this month’s “best of the best” as part of the American Physiological Society’s APSselect program.
St John’s Wort can produce the same adverse reactions as antidepressants, and serious side effects can occur when the two are taken together, according to new University of Adelaide research.
The Food and Drug Administration (FDA) announced today that it will delay enforcement of Track and Trace requirements that were scheduled to go into effect on July 1, 2015, until November 1, 2015. This policy change follows a formal written request by ASHP urging FDA to give hospitals and health systems more time to comply with the regulations.
Vermont scientists have invented a new technique for discovering potentially dangerous drug interactions--before they show up in medical databases like PubMed--by searching millions of tweets on Twitter.
For the first time, researchers have found a way to stop cancer cell growth by targeting the Warburg Effect, a trait of cancer cell metabolism that scientists have been eager to exploit.
Other topics include weight loss, medical marijuana, smart traffic lights, diabetes, heart disease, and more.
Other topics include dietary guidelines, smart traffic lights, breast cancer, and biomarker tests for cancer treatment.
Monte Shaheen, MD, and colleagues from around the country recently published a paper in the New England Journal of Medicine about a promising new treatment for melanoma.
A rigorous analysis of more than 20,000 medical records concludes that erectile dysfunction drugs, such as Viagra, are not a cause of melanoma, an often deadly form of skin cancer, despite the higher risk for the disease among users of these drugs.
Among men in Sweden, use of erectile dysfunctions drugs with phosphodiesterase type 5 inhibitors was associated with a modest but significant increased risk of malignant melanoma, although the pattern of association raises questions about whether this association is causal, according to a study in the June 23/30 issue of JAMA.
A series of fascinating studies at Harvard University showed that many people respond positively to placebo pills — even when they are told that the pills don't have any active ingredients. Researchers at UAB are partnering with a Harvard scientist to test these "open-label" placebos for the first time among cancer survivors.
Patients with atrial fibrillation who stopped taking blood thinners before they had elective surgery had no higher risk of developing blood clots and less risk of major bleeding compared to patients who were given a “bridge” therapy, according to research led by Duke Medicine.
CGRP monoclonal antibodies appear to significantly reduce the frequency of migraine in human clinical trials, potentially changing the landscape for migraine treatment. Headache specialist Sid Kapoor, MD, discusses the enormous potential -- and pitfalls-- facing the drug class' road to FDA approval.
Topics include: treating advanced skin cancer, big data and bioenergy, cancer research, 10 reasons to eat quinoa, sleep issues in the nursing field, advances in cancer surgery, genes for sleep, brain receptor for cocaine addiction, and nano imaging on insect adaptations.
You can whack it with a hammer, attack it with a drill, or even stab it with a screwdriver. But try as you might, you won’t be able to get into this pill dispenser. Which is exactly the idea.
Scientists at The Scripps Research Institute have teamed up with several other institutions and pharmaceutical companies, to publish the first 3D structures of a receptor implicated in many diseases of the brain and in normal physiology throughout the body.
Researchers at University of California, San Diego School of Medicine have made a surprisingly simple discovery: The modification of more than 100 secreted proteins is the work of a single enzyme called Fam20C. The finding is published June 18 by Cell.
Metastatic colorectal cancer patients tend to live longer when they respond to the first line of chemotherapy their doctors recommend. To better predict how patients will respond to chemotherapy drugs before they begin treatment, researchers at University of California, San Diego School of Medicine conducted a proof-of-principle study with a small group of metastatic colorectal cancer patients. The results revealed two genes that could help physicians make more informed treatment decisions for patients with this disease.
Trending news releases with the most views in a single day. Topics include: An anonymous donor for cancer research, solar storms and incidences of rheumatoid arthritis, vulnerabilities in genome’s ‘Dimmer Switches’, new treatments for Alzheimer's, How people make decisions for or against flu vaccinations.
Trending news releases with the most views in a single day. Topics include: new drug for heart disease, astronomy, sleep, stroke, diabetes, materials science, MERS, and U.S. Politics.
A University of Manchester led trial of a new psoriasis drug has resulted in 40 percent of people showing a complete clearance of psoriatic plaques after 12 weeks of treatment and over 90 percent showing improvement.
According to a new study, women experiencing difficulty with time management, attention, organization, memory, and problem solving – often referred to as executive functions – related to menopause may find improvement with a drug already being used to treat attention deficit hyperactivity disorder (ADHD).
In clinical trials, a new drug class known as PCSK9 Inhibitors reduced bad cholesterol markedly and is expected to be approved by the FDA this summer. An expert in lipid management discusses some of the barriers to its use.
In a study published in Science June 12, Case Western Reserve and University of Texas-Southwestern researchers detail how a new drug repaired damage to the colon, liver and bone marrow in animal models — even saving mice who otherwise would have died in a bone marrow transplantation model.
Adults who use proton pump inhibitors are between 16 and 21 percent more likely to experience a heart attack than people who don't use the commonly prescribed antacid drugs, according to a massive new study by Houston Methodist and Stanford University scientists.
It started out as a treatment for arthritis. But steered by science, it could become a first new approach in two decades for treating the damage that diabetes inflicts on the kidneys of millions of people.
Dr. Charles H. Hennekens has done ground-breaking research on the benefits of statins, aspirin, ACE inhibitors, ARBs as well as beta adrenergic blockers. His guidance will assist clinicians to address the clinical and public health challenges to increase utilization of statins in the treatment and prevention of heart attacks and strokes.
A clinical trial of the glucose-control drug sitagliptin among patients with type 2 diabetes and established cardiovascular disease has found it did not raise the risk of major adverse cardiovascular events.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right